Physician profile
Rianne Clark
NPI 1841765344
$4,160.38
in general payments reported to CMS, 2019-2025
42 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2022: $841 · 2023: $890 · 2024: $735 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.87 | 2021-2025 | |
| Novo Nordisk INC | $453.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $399.29 | 2023-2025 | |
| Viiv Healthcare Company | $254.50 | 2022-2025 | Apretude |
| Amgen INC. | $230.11 | 2023-2025 | Repatha, Otezla, Repatha |
| Gilead Sciences, INC. | $208.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.71 | 2021-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $119.07 | 2021-2025 | |
| Lilly USA, LLC | $109.11 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Allergan, INC. | $97.99 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.63 | 2022-2025 | |
| Astellas Pharma US INC | $88.36 | 2023-2025 | Veozah, Myrbetriq |
| Horizon Therapeutics Plc | $83.08 | 2021-2022 | |
| Glaxosmithkline, LLC. | $79.78 | 2025 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $64.72 | 2022-2024 | Quviviq |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rianne Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.